Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Syntara Limited ( (AU:SNT) ) just unveiled an announcement.
Syntara Limited has issued 242,605,411 new fully paid ordinary shares at A$0.027 per share, completing the first tranche of an $8 million two-tranche placement previously announced in April. The capital raising also contemplates a planned share purchase plan of about $2 million, and the company confirms it has met its continuous disclosure and reporting obligations, with no excluded information to disclose under the Corporations Act.
The notice, lodged under section 708A(5)(e) of the Corporations Act, clarifies that the new shares were issued without a prospectus while maintaining compliance with relevant corporate reporting and disclosure rules. This reinforces Syntara’s funding position for its ongoing activities and signals to investors that the company remains in good standing with regulatory requirements as it advances its business strategy.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Syntara Limited stock, see the AU:SNT Stock Forecast page.
More about Syntara Limited
Syntara Limited is an Australia-based company listed on the ASX under the ticker SNT. The company operates in the broader life sciences and therapeutics sector, focusing on drug development activities and related biotechnology initiatives targeting medical markets.
Average Trading Volume: 950,658
Technical Sentiment Signal: Sell
Current Market Cap: A$45.76M
For a thorough assessment of SNT stock, go to TipRanks’ Stock Analysis page.